Search research articles
Contact Us
Filters
Showing results (81-90 of 149) with videos related to
Page
of 15
Sort By:
Lancet (London, England)
|
December 15, 2010
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo, Paola Tacchetti, Francesca Patriarca, et al.
Ejhaem
|
June 19, 2024
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy
Francesca Fazio, Maria Teresa Petrucci, Laura Corvatta, et al.
Blood
|
June 19, 2013
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results
Francesca Gay, Valeria Magarotto, Claudia Crippa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2018
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
Meletios Dimopoulos, Katja Weisel, Niels W C J van de Donk, et al.
The Lancet. Healthy Longevity
|
September 14, 2022
Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study
Fabio Efficace, Gianluca Gaidano, Maria Teresa Petrucci, et al.
European Journal of Haematology
|
November 21, 2008
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts
Francesca Patriarca, Maria T Petrucci, Sara Bringhen, et al.
Stem Cell Research & Therapy
|
April 19, 2015
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study
Pellegrino Musto, Vittorio Simeon, Alberto Grossi, et al.
Leukemia
|
June 9, 2018
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)
Alessandra Larocca, Sandra Maria Dold, Sonja Zweegman, et al.
Blood
|
January 14, 2011
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
Francesca Gay, Alessandra Larocca, Pierre Wijermans, et al.
European Journal of Haematology
|
November 26, 2009
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA
Fortunato Morabito, Massimo Gentile, Stefania Ciolli, et al.
Page
of 15
Search research articles
Search
Showing results (81-90 of 149) with videos related to
Sort By:
Page
of 15
Lancet (London, England)
|
December 15, 2010
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Michele Cavo, Paola Tacchetti, Francesca Patriarca, et al.
Ejhaem
|
June 19, 2024
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy
Francesca Fazio, Maria Teresa Petrucci, Laura Corvatta, et al.
Blood
|
June 19, 2013
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results
Francesca Gay, Valeria Magarotto, Claudia Crippa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2018
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
Meletios Dimopoulos, Katja Weisel, Niels W C J van de Donk, et al.
The Lancet. Healthy Longevity
|
September 14, 2022
Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study
Fabio Efficace, Gianluca Gaidano, Maria Teresa Petrucci, et al.
European Journal of Haematology
|
November 21, 2008
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts
Francesca Patriarca, Maria T Petrucci, Sara Bringhen, et al.
Stem Cell Research & Therapy
|
April 19, 2015
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell'Adulto Multiple Myeloma Working Party study
Pellegrino Musto, Vittorio Simeon, Alberto Grossi, et al.
Leukemia
|
June 9, 2018
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)
Alessandra Larocca, Sandra Maria Dold, Sonja Zweegman, et al.
Blood
|
January 14, 2011
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
Francesca Gay, Alessandra Larocca, Pierre Wijermans, et al.
European Journal of Haematology
|
November 26, 2009
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA
Fortunato Morabito, Massimo Gentile, Stefania Ciolli, et al.
Page
of 15